Sara Hurvitz

Sara Hurvitz is Director of the Breast Oncology Program at UC San Diego Moores Cancer Center and one of the world's leading experts on HER2-directed antibody-drug conjugates. She has played a central role in the clinical development of trastuzumab deruxtecan (T-DXd, Enhertu), serving as a principal investigator on the pivotal DESTINY-Breast series of trials. Her work has redefined the treatment paradigm not only for HER2-positive breast cancer but, crucially, for the newly defined HER2-low category, a patient population previously lacking HER2-directed options. Hurvitz was the lead investigator for DESTINY-Breast03, the landmark head-to-head trial comparing T-DXd to ado-trastuzumab emtansine (T-DM1) in previously treated HER2+ metastatic breast cancer, which demonstrated dramatically superior outcomes for T-DXd and led to its FDA approval as a second-line standard of care. She has also led early-phase studies exploring T-DXd in new combinations and lines of therapy, as well as investigations into biomarkers predicting response. Beyond T-DXd, Hurvitz has contributed to the clinical evaluation of bispecific antibodies, tyrosine kinase inhibitors, and immune checkpoint combinations in HER2+ breast cancer. She is committed to integrating biomarker science into clinical trial design and to training the next generation of breast oncology researchers.